TICKERNERD
Menu
VSTMVSTMHealthcare · Biotechnology

VSTM Stock Forecast: Verastem, Inc. Price Predictions for 2026-2027

Last close, 8 Oct 2026
$8.11
−1.93% on the day

The 10 Wall Street analysts covering Verastem, Inc. hold a median 12-month price target of $14 — +72.6% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 59 of 100 as at 8 Oct 2026 — in the upper half.

Market cap
$701.9M
Ticker Nerd rank
59 / 100
Median analyst target
$14
Analysts covering
10
Revenue$40.1M+1775.4% y/y
Operating income−$32.7M
Net income−$34.7M
Free cash flow−$43.9M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+2.7%
1M
+0.4%
YTD
+5.1%
1Y
−9.3%
From 52W high
−23.8%
From 52W low
+135.1%
$3
$11
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

VSTM stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Verastem, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 8 Oct 2026
59 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Growth
88
Volatility
78
Value
76
Accruals
57
Revisions
53
Size
48
Quality
40
Momentum
38
Issuance
34

Growth (88): Sales and profits are climbing, and climbing faster than before.

Issuance (34): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

VSTM stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on VSTM, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$5$10$15$20Jan 26Apr 26Jul 26Oct 26VSTMHigh $18Median $14Low $11

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says10 analysts
10 Buy0 Hold0 Sell
Low $11Median $14High $18

The green dot is the last close — the median target sits +72.6% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 0 moved their price target up and 3 moved it down.

DateFirmActionRatingTarget
17 Sept 2026Wolfe ResearchInitiatesOutperform—
11 Sept 2026BTIGReiteratesBuy$18
11 Sept 2026HC Wainwright & Co.ReiteratesBuy$18
11 Aug 2026MizuhoMaintainsOutperform$14 → $13
11 Aug 2026MizuhoMaintainsOutperform—
7 Aug 2026GuggenheimMaintainsBuy—
7 Aug 2026GuggenheimMaintainsBuy$14 → $12
7 July 2026RBC CapitalMaintainsOutperform—
7 July 2026RBC CapitalMaintainsOutperform$15 → $14
2 July 2026BTIGMaintainsBuy$18
2 July 2026BTIGMaintainsBuy—
24 June 2026BTIGReiteratesBuy—
24 June 2026HC Wainwright & Co.ReiteratesBuy—
23 June 2026JefferiesMaintainsBuy—
14 May 2026MizuhoMaintainsOutperform—
8 May 2026BTIGMaintainsBuy—
23 Apr 2026BTIGReiteratesBuy—
20 Apr 2026BTIGReiteratesBuy—
10 Apr 2026BTIGReiteratesBuy—
10 Apr 2026HC Wainwright & Co.ReiteratesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. VSTM appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

VSTM vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 8 Oct 2026, Verastem, Inc. returned −9.3% against +16.2% for the S&P 500, dividends included.

VSTM vs S&P 500, last 12 monthsTotal return, rebased to 100
406080100120Jan 26Apr 26Jul 26Oct 26VSTMS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

VSTM analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
1
Analysts cutting
0
Fundamentals

Verastem, Inc. (VSTM) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−2.7×

Cheaper than 87% of US stocks

Price / sales
8.0×

Cheaper than 17% of US stocks

Price / book
8.3×

Cheaper than 11% of US stocks

EV / EBITDA
−4.1×

Cheaper than 78% of US stocks

Growth & margins
Revenue growth (YoY)
1775.4%

Higher than 99% of US stocks

Earnings growth (YoY)
1775.4%

Higher than 98% of US stocks

Gross margin
89.9%

Higher than 96% of US stocks

Operating margin
−81.6%

Higher than 15% of US stocks

Net margin
−231.6%

Higher than 2% of US stocks

Returns & dividend
Return on equity
−471.2%

Higher than 3% of US stocks

Return on assets
−49.6%

Higher than 8% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Verastem, Inc. (VSTM) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Verastem, Inc. has a market value of $701.9M and an enterprise value of $649.8M.

  • Revenue in the twelve months to 30 June 2026: $87.5M. The latest quarter grew 1775.4% year on year.

  • Net income over the same four quarters: −$202.7M, a −231.6% net margin.

  • Free cash flow in the twelve months to 30 June 2026: −$171.8M.

  • Shares outstanding: 90.5M.

  • Trailing P/E: −2.7×; forward P/E: −10.3× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Verastem, Inc. employs 102 people — $858K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 7 Oct 2026

Data provided by Twelve Data

Peers

VSTM vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
VSTMVerastem, Inc.$701.9M
59
DSGNDesign Therapeutics, Inc.$708.6M
61
SLDBSolid Biosciences, Inc.$717.0M
44
CADLCandel Therapeutics, Inc.$707.6M
41
AVTXAvalo Therapeutics, Inc.$706.0M
36
FDMT4D Molecular Therapeutics, Inc.$701.6M
56
DNAGinkgo Bioworks Holdings, Inc.$734.5M
38

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Verastem, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest VSTM news & analysis

Verastem: A Two-For-One Clinical Readout In October And A Commercial Launch

Seeking Alpha · 6 Oct 2026positive

Verastem reported Q2 '26 net product revenues of $25.1M in just the fourth quarter since the launch of Avmapki Fakzynja Co-pack, and is advancing its KRAS G12D inhibitor, VS-7375, across multiple cancers. An October readout from the TARGET-D 101 trial of VS-7375 in solid tumors represents a significant near-term clinical catalyst.

Why it matters — The company is seeing commercial traction with its Co-pack launch and has a potentially pivotal October clinical data readout for VS-7375 approaching.

Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Business Wire · 5 Oct 2026neutral

Verastem Oncology announced it granted 380,500 restricted stock units to 24 new employees and stock options to purchase 50,000 shares to one new employee, under the Nasdaq inducement grant exception. These awards serve as an inducement material to the employees' acceptance of employment with the company.

Why it matters — A VSTM watcher would note that these equity-based grants often reflect the hiring of new staff and typical Nasdaq-listed inducement practices, without indicating any shift in the company's operations or outlook.

Verastem Oncology Announces New RAMP 201 Molecular Profiling and External Control Arm Analyses Describing Outcomes for Avutometinib Plus Defactinib in Recurrent Low-Grade Serous Ovarian Cancer to be Presented at IGCS 2026

Business Wire · 2 Oct 2026positive

Verastem Oncology announced new RAMP 201 molecular profiling and external control arm analyses describing outcomes for avutometinib plus defactinib in recurrent low-grade serous ovarian cancer, to be presented at IGCS 2026. The announcement was made via Business Wire.

Why it matters — This news highlights new clinical data supporting the company's investigational combination therapy in recurrent low-grade serous ovarian cancer, a key program for Verastem.

Verastem Oncology Announces Publication in Gynecologic Oncology of Two-Year Median Follow-Up Data from RAMP 201 Study of AVMAPKI® FAKZYNJA® CO-PACK (avutometinib capsules; defactinib tablets) in Recurrent Low-Grade Serous Ovarian Cancer

Business Wire · 28 Sept 2026positive

Verastem Oncology announced that two-year median follow-up data from its RAMP 201 study of AVMAPKI (avutometinib and defactinib) in recurrent low-grade serous ovarian cancer were published in Gynecologic Oncology. The publication reports durable clinical benefit and a manageable safety profile in this patient population.

Why it matters — A peer-reviewed publication confirming durable long-term efficacy and manageable safety supports confidence in the company's lead product candidate for recurrent LGSOC.

Verastem Oncology Announces Late-Breaking Oral Presentation of RAMP 201 Low-Grade Serous Ovarian Cancer Molecular Profiling and Tumor Biomarker Analysis at IGCS 2026 Annual Global Meeting

Business Wire · 24 Sept 2026positive

Verastem Oncology announced it will present a late-breaking oral presentation of RAMP 201 low-grade serous ovarian cancer molecular profiling and tumor biomarker analysis at the IGCS 2026 Annual Global Meeting. The presentation was announced via a Business Wire release.

Why it matters — The presentation signals progress in Verastem's RAMP 201 clinical program and highlights biomarker data relevant to its low-grade serous ovarian cancer research.

FAQ

Frequently asked questions about VSTM stock

What is the VSTM stock price forecast for 2026-2027?

The 10 Wall Street analysts covering Verastem, Inc. have a median 12-month price target of $14, with estimates ranging from $11 to $18. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is VSTM stock a buy right now?

Of the 10 analysts covering Verastem, Inc., 10 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Verastem, Inc. 59 out of 100 across roughly 4,600 US stocks as at 8 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank VSTM?

As at 8 Oct 2026, Verastem, Inc. ranks 59 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (88 of 100).

Will VSTM stock go up?

No one can know that. What the data says: the median 12-month target from 10 analysts implies +72.6% from the last close, and Ticker Nerd's factor model ranks Verastem, Inc. 59 out of 100 as at 8 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the VSTM stock forecast for 2030?

No analyst covering Verastem, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for VSTM are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $11 to $18 over the next 12 months.

How has VSTM stock performed over the past year?

Verastem, Inc. returned -9.3% over the 12 months to 8 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Verastem, Inc. do?

Verastem Inc. is a biopharmaceutical company focused on developing and commercializing medicines for cancer, with an emphasis on tumors driven by the RAS/MAPK signaling pathway.

What is the latest news on VSTM?

The most recent item we track (Seeking Alpha, 6 Oct 2026): "Verastem: A Two-For-One Clinical Readout In October And A Commercial Launch". Verastem reported Q2 '26 net product revenues of $25.1M in just the fourth quarter since the launch of Avmapki Fakzynja Co-pack, and is advancing its KRAS G12D inhibitor, VS-7375, across multiple cancers. An October readout from the TARGET-D 101 trial of VS-7375 in solid tumors represents a significant near-term clinical catalyst.

Company

About Verastem, Inc.

Verastem Inc. is a biopharmaceutical company focused on developing and commercializing medicines for cancer, with an emphasis on tumors driven by the RAS/MAPK signaling pathway. Verastem Oncology’s current portfolio includes marketed and investigational therapies designed to address difficult-to-treat cancers, including rare ovarian cancer and other solid tumors. The company’s product and pipeline programs center on small-molecule oncology treatments such as RAF/MEK and FAK pathway inhibitors, reflecting a targeted approach to tumor biology. Verastem also works with companion diagnostics and clinical collaborations to support patient selection and study combination regimens. Based in Needham, Massachusetts, Verastem serves the oncology market by advancing therapies intended to improve treatment options across specialized cancer indications.

CEO Mr. Daniel W. Paterson · 102 employees · United States · https://www.verastem.com